

Special Issue

Advances in Melanoma: From Pathogenesis to Personalized Therapy

Message from the Guest Editor

This Special Issue will focus on the latest clinical advancements in melanoma management, emphasizing personalized treatment strategies and real-world applications. Contributions will highlight the evolving role of targeted therapies (BRAF/MEK inhibitors) and immunotherapy (PD-1/CTLA-4 blockade) in improving survival outcomes in advanced melanoma. Key discussions in this area include predictive biomarkers for treatment selection, strategies to overcome therapy resistance, and the integration of novel combination therapies into clinical practice. This Special Issue will also explore emerging diagnostic tools, such as liquid biopsies and imaging advancements, for early detection and monitoring. Additionally, real-world data on treatment sequencing, adjuvant therapy optimization, and long-term survivorship will be addressed. By bridging translational research and clinical practice, this Special Issue will provide actionable insights for oncologists to utilize in enhancing melanoma care. To encompass the entire journey of melanoma care, the latest developments in palliative care, including spiritual care, will be discussed.

Guest Editor

Dr. Patricia Tai

Department of Oncology, University of Saskatchewan, Saskatoon, SK S7N 5A2, Canada

Deadline for manuscript submissions

14 November 2025



Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



mdpi.com/si/238777

Current Oncology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
currentoncology@mdpi.com

[mdpi.com/journal/
currentoncol](https://mdpi.com/journal/currentoncol)





Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



[mdpi.com/journal/
currentcol](https://mdpi.com/journal/currentcol)



About the Journal

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Oncology)